Pemetrexed potentiates γδ T cell-based immunotherapy in NSCLC through ATM-STING-NF-κB-mediated induction of NKG2D ligands
International Immunopharmacology · 2026-10 · 186 · 117115
DOI: 10.1016/j.intimp.2026.117115 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-10. Verfasst von Meng-Yu Hung und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Research, Advanced Therapeutic & Pharmaceutical Center, China Medical University Hospital, Taichung, Taiwan; Department of Life…. Hauptthemen laut MEDLINE: Pemetrexed, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Adoptive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Science and Technology Council.
Abstract (Originalsprache)
Adoptive T-cell therapy is a promising strategy for cancer immunotherapy; however, its efficacy is often limited by the immunosuppressive tumor microenvironment. γδ T cells, particularly the Vγ9Vδ2 subset, exhibit innate-like cytotoxicity and are emerging candidates for adoptive immunotherapy. Pemetrexed, an antifolate chemotherapeutic agent, has documented immunomodulatory effects in αβ T-cell settings; however, its impact on γδ T-cell antitumor responses remains insufficiently defined. Here, Vγ9Vδ2 T cells were isolated and expanded from healthy-donor peripheral blood mononuclear cells (PMBCs) and co-cultured with non-small cell lung cancer (NSCLC) cells with or without pemetrexed pretreatment. Pemetrexed significantly enhanced γδ T cell-mediated cytotoxicity compared with either treatment alone. Mechanistically, pemetrexed increased the expression of NKG2D ligands, including MHC class I chain-related proteins A/B (MICA/B) and UL16-binding proteins (ULBPs), through the ataxia-telangiectasia mutated (ATM)-stimulator of interferon genes (STING)-nuclear factor-κB (NF-κB) signaling axis. ATM activation triggered cyclic GMP-AMP synthase-independent STING signaling and preferentially activated NF-κB rather than interferon regulatory factor 3 (IRF3), thereby promoting transcriptional upregulation of NKG2D ligands and improving tumor recognition by γδ T cells. Consistent with the cell-line findings, pemetrexed increased MICA/B and ULBP2/5/6 expression in NSCLC patient-derived organoids. Furthermore, in an in vivo NSCLC animal model, combined pemetrexed and adoptive γδ T-cell therapy suppressed tumor growth more effectively than either treatment alone and was accompanied by increased NKG2D ligand expression. Collectively, these findings reveal a tumor-sensitizing mechanism by which pemetrexed potentiates γδ T-cell antitumor function and support combining pemetrexed with γδ T cell-based immunotherapy for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Research, Advanced Therapeutic & Pharmaceutical Center, China Medical University Hospital, Taichung, Taiwan; Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.
- Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan; Master in Senior Health and Exercise Science, Tunghai University, Taichung, Taiwan.
- Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.
- Department of Medical Research, Advanced Therapeutic & Pharmaceutical Center, China Medical University Hospital, Taichung, Taiwan; Drug Development Center, China Medical University, Taichung, Taiwan; Department of Neuro…
- Department of Medical Research, Advanced Therapeutic & Pharmaceutical Center, China Medical University Hospital, Taichung, Taiwan; Drug Development Center, China Medical University, Taichung, Taiwan; Graduate Institute…
- Department of Medical Research, Advanced Therapeutic & Pharmaceutical Center, China Medical University Hospital, Taichung, Taiwan.
Förderung
- National Science and Technology Council
Zitieren
APA
Hung, M. Y., Lin, H., Li, Y. H., Cho, D. Y., Chiu, S. C., Pan, C. M., Huang, S. W., Fang, H. Y., Chen, Y. W., Kan, K. W., Huang, K. C., & Chen, M. C. (2026). Pemetrexed potentiates γδ T cell-based immunotherapy in NSCLC through ATM-STING-NF-κB-mediated induction of NKG2D ligands. International Immunopharmacology, 186, 117115. https://doi.org/10.1016/j.intimp.2026.117115
Vancouver
Hung MY, Lin H, Li YH, Cho DY, Chiu SC, Pan CM, et al. Pemetrexed potentiates γδ T cell-based immunotherapy in NSCLC through ATM-STING-NF-κB-mediated induction of NKG2D ligands. International Immunopharmacology. 2026;186:117115. doi:10.1016/j.intimp.2026.117115
BibTeX
@article{Hung2026,
author = {Hung, Meng-Yu and Lin, Ho and Li, Yu-Hsuan and Cho, Der-Yang and Chiu, Shao-Chih and Pan, Chih-Ming and Huang, Shi-Wei and Fang, Hsin-Yuan and Chen, Yi-Wen and Kan, Kai-Wen and Huang, Kevin Chih-Yang and Chen, Mei-Chih},
title = {Pemetrexed potentiates γδ T cell-based immunotherapy in NSCLC through ATM-STING-NF-κB-mediated induction of NKG2D ligands},
journal = {International Immunopharmacology},
year = {2026},
volume = {186},
pages = {117115},
doi = {10.1016/j.intimp.2026.117115}
}
EUVIMED